Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2019-12-13 Capital/Financing Update
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Board Meeting — Fund Raising
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for 18 December 2019. The purpose of the meeting includes considering and approving a proposal for raising funds through equity shares or convertible securities via Qualified Institutional Placement or preferential allotment. It also mentions that if the proposal is approved, shareholder approval will be sought through Postal Ballot or other means. The document references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures related to board meetings and corporate actions. The document is an announcement of a board meeting and potential capital raising, not the actual report or detailed financial data. It is also relatively short (1666 characters). Therefore, it fits best under Capital/Financing Update (CAP) as it informs about financing activities to be discussed and potentially approved by the board.
2019-12-13 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended 30 September 2019, submitted to stock exchanges in compliance with SEBI regulations. It contains detailed transaction data with related parties, including key management personnel and enterprises with significant influence, for the specified half-year period. The document is not an announcement of a report but the actual disclosure of financial transactions related to related parties. This type of disclosure aligns with regulatory requirements for related party transactions, which is typically part of regulatory filings but here it is a specific disclosure under SEBI Listing Obligations. Given the nature and content, it fits best under Regulatory Filings (RNS) as it is a compliance disclosure document rather than a full financial report or other specific category.
2019-11-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on 6 November 2019 discussing the company's financial results for the quarter and half year ended 30 September 2019. It includes detailed management commentary on financial performance, operational highlights, and a Q&A session with analysts. The presence of a full transcript of the call, including management and analyst dialogue, confirms this is a Call Transcript. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Call Transcript (CT).
2019-11-19 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated 6 November 2019 presenting financial highlights for Q2FY20 and H1FY20, including sales, net profit, EPS, and division-wise revenue contributions. It contains detailed financial data and analysis for the quarter and half-year periods, including profitability margins and business overview commentary. The presence of actual financial figures and period-specific results indicates this is a comprehensive interim financial report rather than a brief earnings release or announcement. The document length (7972 characters) supports it being a substantive report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2020
2019-11-06 English
Financial Result Updates
Regulatory Filings
2019-11-06 English
Outcome of Board Meeting
Regulatory Filings
2019-11-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.